Clinical and Genetic Correlates of the Gut Microbiome and Relation to Cardiometabolic Risk

The human gut harbors trillions of microbes that play dynamic roles in health. While the microbiome contributes to many cardiometabolic traits by modulating host inflammation and metabolism, there is an incomplete understanding regarding the extent and mechanisms by which individual microbes impact risk and development of cardiovascular disease (CVD). The Framingham Heart Study (FHS) is a multi-generational observational study following participants over decades to identify risk factors for CVD by correlating genetic and phenotypic factors with clinical outcomes. As a large-scale population-based cohort with extensive clinical phenotyping, FHS provides a rich landscape to explore the relationships between the gut microbiome and cardiometabolic traits

Available Data sets

Currently we have the following data set available in the 'Authorized Access' area of dbGaP.

1. Cholesterol Metabolism by Uncultured Human Gut Bacteria Influences Host Cholesterol

This data set, consisting of metagenome FASTQ data from 624 FHS participants, was released in conjunction with PMID: [32544460](https://pubmed.ncbi.nlm.nih.gov/32544460/).

人体肠道内定植着数以万亿计的微生物，它们在机体健康中发挥着动态调控作用。尽管肠道菌群可通过调控宿主炎症与代谢过程影响诸多心血管代谢特征，但目前对于单个微生物菌株影响心血管疾病（cardiovascular disease, CVD）发生风险与病程的具体程度及分子机制，仍尚未完全阐明。弗雷明汉心脏研究（Framingham Heart Study, FHS）是一项多代队列观察性研究，通过对数十年随访的参与者的遗传与表型因素与临床结局进行关联分析，以明确心血管疾病的风险因子。作为一项具备大规模人群队列基础且覆盖全面临床表型分型的研究，FHS为探索肠道菌群与心血管代谢特征之间的关联提供了极佳的研究场景。

可用数据集
目前，dbGaP的"授权访问"专区中可获取以下数据集：
1. 未培养人肠道细菌的胆固醇代谢可影响宿主胆固醇水平
该数据集包含624名FHS参与者的宏基因组FASTQ测序数据，与对应研究论文的PMID：[32544460](https://pubmed.ncbi.nlm.nih.gov/32544460/)同步发布。